Lixisenatide
Also known as: Adlyxin · Lyxumia
A fast-acting once-daily GLP-1 agonist specifically targeting post-meal blood sugar spikes, often combined with basal insulin.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~3 hours
10–20 mcg daily
Subcutaneous injection
Mechanism of Action
Short-acting GLP-1 receptor agonist providing intense postprandial glycemic control through localized gut and pancreatic effects.
Key Research Areas
Frequently Asked Questions
What is Lixisenatide?▾
How does Lixisenatide work?▾
What is the recommended dosage for Lixisenatide?▾
What is the half-life of Lixisenatide?▾
Is Lixisenatide FDA approved?▾
Ready to get started with Lixisenatide?
Order from our COA-verified partner — free US shipping, pharmaceutical-grade quality.
Research Disclaimer
The information provided about Lixisenatide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.